(Q41564562)

3 October 2017

1 reference

title

Systemic chemotherapy of transitional cell carcinoma of the urothelium (English)

1 reference

transitional cell carcinoma

3 October 2017

main subject

1 reference

W M Brinkley

1

1 reference

3 October 2017

F M Torti

series ordinal

2

1 reference

3 October 2017

publication date

1 September 1997

1 reference

Journal of Surgical Oncology

3 October 2017

published in

1 reference

3 October 2017

volume

13

1 reference

3 October 2017

issue

5

1 reference

3 October 2017

page(s)

365-375

1 reference

3 October 2017

cites work

Cancer statistics, 1996.

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291098-2388%28199709%2F10%2913%3A5%3C365%3A%3AAID-SSU11%3E3.0.CO%3B2-M

21 January 2018

Cancer statistics, 1984.

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291098-2388%28199709%2F10%2913%3A5%3C365%3A%3AAID-SSU11%3E3.0.CO%3B2-M

Biology and management of bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291098-2388%28199709%2F10%2913%3A5%3C365%3A%3AAID-SSU11%3E3.0.CO%3B2-M

Chemotherapy of advanced transitional-cell carcinoma of the bladder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291098-2388%28199709%2F10%2913%3A5%3C365%3A%3AAID-SSU11%3E3.0.CO%3B2-M

Cisplatin, methotrexate and vinblastine plus surgical restaging for patients with advanced transitional cell carcinoma of the urothelium

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291098-2388%28199709%2F10%2913%3A5%3C365%3A%3AAID-SSU11%3E3.0.CO%3B2-M

Cis-diamminedichloroplatinum (DDP) as initial treatment of invasive bladder cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291098-2388%28199709%2F10%2913%3A5%3C365%3A%3AAID-SSU11%3E3.0.CO%3B2-M

Initial intravenous cis-platinum therapy: improved management for invasive high risk bladder cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291098-2388%28199709%2F10%2913%3A5%3C365%3A%3AAID-SSU11%3E3.0.CO%3B2-M

Methotrexate, cisplatin and carboplatin as single agents and in combination for metastatic bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291098-2388%28199709%2F10%2913%3A5%3C365%3A%3AAID-SSU11%3E3.0.CO%3B2-M

A randomized trial of cisplatin versus cisplatin plus methotrexate in advanced cancer of the urothelial tract

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291098-2388%28199709%2F10%2913%3A5%3C365%3A%3AAID-SSU11%3E3.0.CO%3B2-M

Methotrexate: an active drug in bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291098-2388%28199709%2F10%2913%3A5%3C365%3A%3AAID-SSU11%3E3.0.CO%3B2-M

Chemotherapy of urothelial tract tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291098-2388%28199709%2F10%2913%3A5%3C365%3A%3AAID-SSU11%3E3.0.CO%3B2-M

Doxorubicin chemotherapy in advanced transitional cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291098-2388%28199709%2F10%2913%3A5%3C365%3A%3AAID-SSU11%3E3.0.CO%3B2-M

Adriamycin in advanced urinary tract cancer.Experience in 42 patients and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291098-2388%28199709%2F10%2913%3A5%3C365%3A%3AAID-SSU11%3E3.0.CO%3B2-M

Dose response evaluation of adriamycin in human neoplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291098-2388%28199709%2F10%2913%3A5%3C365%3A%3AAID-SSU11%3E3.0.CO%3B2-M

Chemotherapy in invasive carcinoma of the bladder. A review of phase II trials in Egypt

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291098-2388%28199709%2F10%2913%3A5%3C365%3A%3AAID-SSU11%3E3.0.CO%3B2-M

Gallium nitrate in advanced bladdercarcinoma: Southwest oncology group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291098-2388%28199709%2F10%2913%3A5%3C365%3A%3AAID-SSU11%3E3.0.CO%3B2-M

Mitoxantrone in advanced bladder carcinoma. A phase II study of the EORTC Genito-urinary Tract Cancer Cooperative Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291098-2388%28199709%2F10%2913%3A5%3C365%3A%3AAID-SSU11%3E3.0.CO%3B2-M

Significant activity of paclitaxel in advanced transitional-cell carcinoma of the urothelium: a phase II trial of the Eastern Cooperative Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291098-2388%28199709%2F10%2913%3A5%3C365%3A%3AAID-SSU11%3E3.0.CO%3B2-M

Weekly gemcitabine in advanced bladder cancer: a preliminary report from a phase I study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291098-2388%28199709%2F10%2913%3A5%3C365%3A%3AAID-SSU11%3E3.0.CO%3B2-M

Advanced transitional cell bladder cancer: a treatable disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291098-2388%28199709%2F10%2913%3A5%3C365%3A%3AAID-SSU11%3E3.0.CO%3B2-M

Cisplatin, methotrexate, and vinblastine (CMV): an effective chemotherapy regimen for metastatic transitional cell carcinoma of the urinary tract. A Northern California Oncology Group study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291098-2388%28199709%2F10%2913%3A5%3C365%3A%3AAID-SSU11%3E3.0.CO%3B2-M

The fate of the bladder in patients with metastatic bladder cancer treated with cisplatin, methotrexate and vinblastine: a Northern California Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291098-2388%28199709%2F10%2913%3A5%3C365%3A%3AAID-SSU11%3E3.0.CO%3B2-M

Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291098-2388%28199709%2F10%2913%3A5%3C365%3A%3AAID-SSU11%3E3.0.CO%3B2-M

M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced transitional cell carcinoma of the urothelium

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291098-2388%28199709%2F10%2913%3A5%3C365%3A%3AAID-SSU11%3E3.0.CO%3B2-M

Escalated therapy for refractory urothelial tumors: methotrexate-vinblastine-doxorubicin-cisplatin plus unglycosylated recombinant human granulocyte-macrophage colony-stimulating factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291098-2388%28199709%2F10%2913%3A5%3C365%3A%3AAID-SSU11%3E3.0.CO%3B2-M

Dose-intensification of MVAC with recombinant granulocyte colony-stimulating factor as initial therapy in advanced urothelial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291098-2388%28199709%2F10%2913%3A5%3C365%3A%3AAID-SSU11%3E3.0.CO%3B2-M

Effect of relative cumulative dose-intensity on survival of patients with urothelial cancer treated with M-VAC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291098-2388%28199709%2F10%2913%3A5%3C365%3A%3AAID-SSU11%3E3.0.CO%3B2-M

Carboplatin, methotrexate, and vinblastine in the treatment of patients with advanced urothelial cancer. A phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291098-2388%28199709%2F10%2913%3A5%3C365%3A%3AAID-SSU11%3E3.0.CO%3B2-M

Carboplatin and 5-fluorouracil in poor performance status patients with advanced urothelial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291098-2388%28199709%2F10%2913%3A5%3C365%3A%3AAID-SSU11%3E3.0.CO%3B2-M

Chemotherapy for metastatic transitional carcinoma of the urinary tract. A prospective trial of methotrexate, adriamycin, and cyclophosphamide (MAC) with cis-platinum for failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291098-2388%28199709%2F10%2913%3A5%3C365%3A%3AAID-SSU11%3E3.0.CO%3B2-M

Vinblastine and methotrexate for advanced bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291098-2388%28199709%2F10%2913%3A5%3C365%3A%3AAID-SSU11%3E3.0.CO%3B2-M

Phase II trial of vinblastine, ifosfamide, and gallium combination chemotherapy in metastatic urothelial carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291098-2388%28199709%2F10%2913%3A5%3C365%3A%3AAID-SSU11%3E3.0.CO%3B2-M

The role of adjuvant chemotherapy following cystectomy for invasive bladder cancer: a prospective comparative trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291098-2388%28199709%2F10%2913%3A5%3C365%3A%3AAID-SSU11%3E3.0.CO%3B2-M

Neoadjuvant cisplatin, methotrexate and vinblastine for muscle-invasive bladder cancer: long-term followup

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291098-2388%28199709%2F10%2913%3A5%3C365%3A%3AAID-SSU11%3E3.0.CO%3B2-M

Cis-diamminedichloroplatinum as a therapeutic agent in metastatic transitional cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291098-2388%28199709%2F10%2913%3A5%3C365%3A%3AAID-SSU11%3E3.0.CO%3B2-M

Cis-diamminedichloride platinum II in the treatment of advanced bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291098-2388%28199709%2F10%2913%3A5%3C365%3A%3AAID-SSU11%3E3.0.CO%3B2-M

A phase 2 study of Cis-platinum in patients with recurrent bladder carcinoma. The London and Oxford Co-operative Urological Cancer Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291098-2388%28199709%2F10%2913%3A5%3C365%3A%3AAID-SSU11%3E3.0.CO%3B2-M

Cis-diamminedichloroplatinum (II) in locally advanced and metastatic urothelial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291098-2388%28199709%2F10%2913%3A5%3C365%3A%3AAID-SSU11%3E3.0.CO%3B2-M

A comparison of cisplatin and the combination of cisplatin and cyclophosphamide in advanced urothelial cancer. A National Bladder Cancer Collaborative Group A Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291098-2388%28199709%2F10%2913%3A5%3C365%3A%3AAID-SSU11%3E3.0.CO%3B2-M

Comparative activity and toxicity of cis-diamminedichloroplatinum (DDP) and a combination of doxorubicin, cyclophosphamide, and DDP in disseminated transitional cell carcinomas of the urinary tract

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291098-2388%28199709%2F10%2913%3A5%3C365%3A%3AAID-SSU11%3E3.0.CO%3B2-M

Phase III comparison of cisplatin alone versus cisplatin, doxorubicin and cyclophosphamide in the treatment of bladder (urothelial) cancer: a Southeastern Cancer Study Group trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291098-2388%28199709%2F10%2913%3A5%3C365%3A%3AAID-SSU11%3E3.0.CO%3B2-M

Phase II evaluation of adriamycin in human neoplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291098-2388%28199709%2F10%2913%3A5%3C365%3A%3AAID-SSU11%3E3.0.CO%3B2-M

Single-drug chemotherapy with 5-FU and adriamycin in metastatic bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291098-2388%28199709%2F10%2913%3A5%3C365%3A%3AAID-SSU11%3E3.0.CO%3B2-M

Adriamycin versus adriamycin plus cis-diamminedichloroplatinum (DDP) in advanced transitional cell bladder carcinoma. A Southwest Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291098-2388%28199709%2F10%2913%3A5%3C365%3A%3AAID-SSU11%3E3.0.CO%3B2-M

A phase II evaluation of a 3-drug combination of cyclophosphamide, doxorubicin and 5-fluorouracil and of 5-fluorouracil in patients with advanced bladder carcinoma or stage D prostatic carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291098-2388%28199709%2F10%2913%3A5%3C365%3A%3AAID-SSU11%3E3.0.CO%3B2-M

A phase II study of 5-fluorouracil and high dose folinic acid in cisplatin-refractory metastatic bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291098-2388%28199709%2F10%2913%3A5%3C365%3A%3AAID-SSU11%3E3.0.CO%3B2-M

Phase II trial of vinblastine sulfate for metastatic urothelial tract tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291098-2388%28199709%2F10%2913%3A5%3C365%3A%3AAID-SSU11%3E3.0.CO%3B2-M

Clinical trial of VP 16--213 (NSC 141540) I.V. twice weekly in advanced neoplastic disease: a study by the Cancer and Leukemia Group B

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291098-2388%28199709%2F10%2913%3A5%3C365%3A%3AAID-SSU11%3E3.0.CO%3B2-M

Oral piritrexim in advanced bladder cancer: an effective drug after progression on MVAC chemotherapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291098-2388%28199709%2F10%2913%3A5%3C365%3A%3AAID-SSU11%3E3.0.CO%3B2-M

Continuous infusion gallium nitrate for patients with advanced refractory urothelial tract tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291098-2388%28199709%2F10%2913%3A5%3C365%3A%3AAID-SSU11%3E3.0.CO%3B2-M

The management of advanced bladder carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291098-2388%28199709%2F10%2913%3A5%3C365%3A%3AAID-SSU11%3E3.0.CO%3B2-M

Cyclophosphamide, adriamycin and cisplatin combination chemotherapy in advanced bladder carcinoma: an EORTC phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291098-2388%28199709%2F10%2913%3A5%3C365%3A%3AAID-SSU11%3E3.0.CO%3B2-M

Phase II trial of sequentially administered cisplatin, cyclophosphamide and doxorubicin for urothelial tract tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291098-2388%28199709%2F10%2913%3A5%3C365%3A%3AAID-SSU11%3E3.0.CO%3B2-M

Diamminedichloride platinum II and cyclophosphamide in the treatment of advanced urothelial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291098-2388%28199709%2F10%2913%3A5%3C365%3A%3AAID-SSU11%3E3.0.CO%3B2-M

Combination chemotherapy with cisplatin and VM-26 in advanced transitional cell carcinoma of the bladder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291098-2388%28199709%2F10%2913%3A5%3C365%3A%3AAID-SSU11%3E3.0.CO%3B2-M

The treatment of advanced bladder cancer with methotrexate and cis-platinum—a pharmacokinetic study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291098-2388%28199709%2F10%2913%3A5%3C365%3A%3AAID-SSU11%3E3.0.CO%3B2-M

Cis-platin and methotrexate in the treatment of transitional cell carcinoma of the urinary tract

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291098-2388%28199709%2F10%2913%3A5%3C365%3A%3AAID-SSU11%3E3.0.CO%3B2-M

Combination chemotherapy with cisplatin and methotrexate in advanced transitional cell cancer of the bladder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291098-2388%28199709%2F10%2913%3A5%3C365%3A%3AAID-SSU11%3E3.0.CO%3B2-M

Paclitaxel, cisplatin and methotrexate combination chemotherapy is active in the treatment of refractory urothelial malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291098-2388%28199709%2F10%2913%3A5%3C365%3A%3AAID-SSU11%3E3.0.CO%3B2-M

Accelerated cisplatin-based chemotherapy for advanced bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291098-2388%28199709%2F10%2913%3A5%3C365%3A%3AAID-SSU11%3E3.0.CO%3B2-M

Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291098-2388%28199709%2F10%2913%3A5%3C365%3A%3AAID-SSU11%3E3.0.CO%3B2-M

A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291098-2388%28199709%2F10%2913%3A5%3C365%3A%3AAID-SSU11%3E3.0.CO%3B2-M

Primary methotrexate, vinblastine, doxorubicin and cisplatin chemotherapy and bladder preservation in locally invasive bladder cancer: a 5-year followup

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291098-2388%28199709%2F10%2913%3A5%3C365%3A%3AAID-SSU11%3E3.0.CO%3B2-M

Phase II study of a new combined primary chemotherapy regimen, intravenous methotrexate and vincristine and intraarterial adriamycin and cisplatin, for locally advanced urinary bladder cancer: preliminary results

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291098-2388%28199709%2F10%2913%3A5%3C365%3A%3AAID-SSU11%3E3.0.CO%3B2-M

Comparison between a cisplatin-containing regimen and a carboplatin-containing regimen for recurrent or metastatic bladder cancer patients. A randomized phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291098-2388%28199709%2F10%2913%3A5%3C365%3A%3AAID-SSU11%3E3.0.CO%3B2-M

Adjuvant chemotherapy of bladder cancer: a preliminary report

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291098-2388%28199709%2F10%2913%3A5%3C365%3A%3AAID-SSU11%3E3.0.CO%3B2-M

Advanced Bladder Cancer (Stages pT3b, pT4a, pN1 and pN2): Improved Survival after Radical Cystectomy and 3 Adjuvant Cycles of Chemotherapy. Results of a Controlled Prospective Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291098-2388%28199709%2F10%2913%3A5%3C365%3A%3AAID-SSU11%3E3.0.CO%3B2-M

Adjuvant cisplatin chemotherapy following cystectomy for bladder cancer: results of a prospective randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291098-2388%28199709%2F10%2913%3A5%3C365%3A%3AAID-SSU11%3E3.0.CO%3B2-M

Adjuvant methotrexate, vinblastine and cisplatin chemotherapy for invasive transitional cell carcinoma: Taiwan experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291098-2388%28199709%2F10%2913%3A5%3C365%3A%3AAID-SSU11%3E3.0.CO%3B2-M

CMV front-line chemotherapy in transitional bladder carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291098-2388%28199709%2F10%2913%3A5%3C365%3A%3AAID-SSU11%3E3.0.CO%3B2-M

Neoadjuvant m-vac (methotrexate, vinblastine, doxorubicin, and cisplatin) for infiltrating transitional cell carcinoma of the bladder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291098-2388%28199709%2F10%2913%3A5%3C365%3A%3AAID-SSU11%3E3.0.CO%3B2-M

Five-year followup of a prospective trial of radical cystectomy and neoadjuvant chemotherapy: Nordic Cystectomy Trial I. The Nordic Cooperative Bladder Cancer Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291098-2388%28199709%2F10%2913%3A5%3C365%3A%3AAID-SSU11%3E3.0.CO%3B2-M

10.1002/(SICI)1098-2388(199709/10)13:5<365::AID-SSU11>3.0.CO;2-M

21 January 2018

Identifiers

DOI

1 reference

3 October 2017

1 reference